Hoba Therapeutics

Hoba Therapeutics, based in Denmark, specializes in developing innovative biopharmaceutical products addressing chronic pain and sensorineural hearing loss through advanced therapeutic solutions. Founded in 2016, Hoba Therapeutics operates from Copenhagen, Denmark, focusing on biopharmaceuticals. The company has conducted a total of 4 deals, with the most recent deal dated October 1, 2023. In December 2023, Hoba Therapeutics raised EUR 23 million in Series A funding, co-led by Indaco Venture Partners and Medical Incubator Japan, alongside returning investors such as Novo Holdings and Eir Ventures.

Kenneth Petersen is the founder, while Torsten Madsen serves as the CEO. Hoba Therapeutics specializes in developing biopharmaceutical products aimed at addressing chronic pain and sensorineural hearing loss. Their lead products include HB-086, targeting chemotherapy-induced peripheral neuropathy and trigeminal neuralgia, and HB-097, focused on ototoxic hearing loss. These products utilize neurotrophic factors critical for nerve cell growth and maintenance, targeting healthcare providers and pharmaceutical partners across Europe and North America.

Hoba Therapeutics generates revenue through partnerships and collaborations with pharmaceutical companies and healthcare entities, focusing on licensing agreements and milestone payments tied to the clinical development of HB-086 and HB-097. The company's revenue model anticipates structured payments related to development milestones and royalties from future product sales. With the EUR 23 million raised in Series A funding, Hoba Therapeutics plans to advance its product HB-086 through late pre-clinical development. The company aims to expand its presence in European and North American markets, enhancing partnerships that support the commercialization of its therapeutics.

The strategic use of recent funding is geared towards positioning Hoba for growth in addressing unmet medical needs in chronic pain and hearing loss.